Financial Performance - Net sales for Q2 2025 were $143.6 million, a 20% increase year-over-year[18] - Adjusted EBITDA for Q2 2025 increased by $42 million, or 514%, year-over-year, reaching $122 million[18] - New orders increased by 28% year-over-year, totaling $1758 million[19] - Backlog increased by 81% year-over-year, reaching $2699 million[19] - The company updated its 2025 guidance with net sales expected to be between $535 million and $555 million, adjusted EBITDA between $40 million and $44 million, and free cash flow between $15 million and $25 million[19] Segment Performance - Infrastructure Solutions net sales increased by 224% in Q2 2025[37] - Rail, Technologies, and Services net sales decreased by 112% in Q2 2025[31] - Precast Concrete sales improved 360%[40] - Protective Coatings improved 474%[40] Capital Management - Net debt decreased by $66 million year-over-year to $774 million[18] - The company repurchased 108,020 shares of common stock for $22 million, representing approximately 10% of outstanding shares[18]

Q2 2025 Financial Performance - The company's Q2 2025 revenue reached $103 million[39] - Adjusted EBITDA was $7.1 million with a 7% margin[39] - Contribution ex-TAC margin was 46%[39] - Non-GAAP net income was $12 million, resulting in a diluted non-GAAP EPS of $0.26[39] - Cash flow from operations amounted to $21.3 million[39] Growth & Channel Performance - DOOH revenue increased by 35% year-over-year[36, 54], reaching $17.6 million[54] - Retail Media revenue increased by 27% year-over-year[36, 46] - Web revenue increased by 5% year-over-year[22, 54], reaching $53.1 million[54] - CTV revenue decreased by 5% year-over-year[36, 43], reaching $9.7 million[54] - Search revenue decreased by 35% year-over-year[54], reaching $22.4 million[54] Strategic Initiatives & Outlook - The company reiterates its FY2025 revenue guidance of $430 million to $450 million[37, 81] - The company expects an Adjusted EBITDA margin of 10% and an Adjusted EBITDA/Contribution ex-TAC margin of 22% for FY2025[81]

Financial Performance - Total revenue reached $25.7 million[2], compared to $28.4 million in Q2'24[2], a decrease of approximately 9.5% - Non-GAAP earnings per share were 7 cents[2], down from 17 cents in Q2'24[2] - GAAP earnings per share were a loss of 15 cents[2], compared to a loss of 1 cent in Q2'24[2] - Licensing and related royalties revenue was $15 million[4] in Q2'25, compared to $17.3 million[4] in Q2'24, a decrease of approximately 13% - Non-GAAP operating income was $1.8 million[4] in Q2'25, compared to $4.4 million[4] in Q2'24, a decrease of approximately 59% - Non-GAAP net income was $0.8 million[4] in Q2'25, compared to $4.2 million[4] in Q2'24, a decrease of approximately 81% Business Highlights - The company signed four new NPU agreements during the quarter[1] - The company returned $6.2 million to shareholders via stock repurchase of 300,000 shares[9] Shipment Data - Total units shipped reached 488 million[8], including 55 million smartphones[8] and 433 million smart edge devices (excluding smartphones)[8] - Smart Edge shipments include 254 million Bluetooth units[8], 62 million Wi-Fi units[8], and 66 million Cellular IoT units[8] Financial Stability - The company has $157 million in cash, cash equivalents, marketable securities, and bank deposits at the end of Q2, and is debt free[9]

Financial Performance - Total revenue increased by 38% year-over-year to $104.1 million[17] - Adjusted EBITDA increased by 58% year-over-year to $21.6 million[17] - Adjusted EBITDA gross margins increased from 64% to 67% year-over-year[17] - Service revenue grew sequentially by 6% and now represents 83% of total revenue[17, 56] - Net debt to EBITDA ratio improved to 2.97x compared to 3.17x in the prior quarter[17] Go-to-Market Momentum - New logo wins increased sequentially by 14% QoQ, with over 175 B2B customers[18] - AI video ARR bookings increased by 52% compared to the previous quarter, driven by indirect channel partners[18] - In-warehouse recurring revenue increased by 24% year-over-year[19] - ARR pipeline build increased by 19% compared to the prior quarter[19] Key Wins and Partnerships - Secured strategic deals with TCV ranging from $400K+ to $750K+ with companies in logistics, food & beverage, rental & leasing, agriculture, and manufacturing[21] - Partnered with MTN Business, one of the world's largest mobile network operators with $7.4 billion annual revenue and 297 million customers, to accelerate enterprise IoT adoption[22, 23] - Won a large-scale operation-wide deployment with SIXT Rental, focusing on AI-powered control over costs, productivity, and accountability[24, 25] Transformation Initiatives - Actioned $11 million in annualized savings in Q1 FY26, part of the $18 million committed for FY26[68, 70] - Expects Net Debt to EBITDA to improve from ~3.25 times at year end FY25 to less than 2.25 times at year end FY26[63, 64]

Business Overview - Kymera Therapeutics is developing oral degraders with a biologics-like profile to disrupt the immunology market[16] - The company aims to deliver a total of 10 new investigational degrader drugs into the clinic by 2026[12] - Kymera has approximately $1 billion in cash and equivalents, providing a runway into the second half of 2028[15] - The company has dosed over 400 healthy volunteers/patients to date across its clinical pipeline[15] KT-621 (STAT6 degrader) - Phase 1 healthy volunteer trial achieved >90% STAT6 degradation in blood and skin[20] - Single doses of KT-621 achieved >95% mean STAT6 degradation at doses of 75 mg or greater[26] - Multiple daily doses of KT-621 achieved complete STAT6 degradation in blood and skin at doses of ≥50 mg[30, 31] - KT-621 showed robust inhibition of TARC and Eotaxin-3 biomarkers, comparable/superior to published dupilumab data[32] - Phase 1b trial in Atopic Dermatitis (AD) patients is ongoing, with data expected in Q4 2025[37, 38] KT-579 (IRF5 degrader) - KT-579 is a potential first-in-class, potent, selective, oral IRF5 degrader[40, 41] - Phase 1 trial is expected to start in early 2026[43] Financials - Collaboration revenue for the three months ended June 30, 2025 was $25650 thousand, compared to $33576 thousand for the six months ended June 30, 2025[44] - Research and development expenses for the three months ended June 30, 2025 were $78388 thousand, compared to $158643 thousand for the six months ended June 30, 2025[44]

Q2 FY25 Financial Highlights - Revenue reached $299 million, representing a 27% year-over-year growth[5] - The company saw a 36% year-over-year increase in customers with ARR (Annual Recurring Revenue) exceeding $50,000, totaling 3,702 customers[5] - Net dollar retention rate for customers with ARR over $50,000 was 116%[5] - Gross margin stood strong at 90%[5] - Adjusted free cash flow was $64 million, which is 21% of the revenue[5] Customer Base Growth - Total customers increased to 245,000 in FY24[16], reflecting a 22% CAGR (Compound Annual Growth Rate) from 2019 to 2024[17, 18] - Customers with ARR over $50,000 grew by 36% year-over-year[25] - Customers with ARR exceeding $100,000 also increased, showing a 46% year-over-year growth[25] Revenue and ARR Trends - The trend shows an increasing percentage of total ARR coming from larger customers, with those having over $100,000 ARR accounting for 38% of the total[28] - Customers with over $50,000 ARR contribute 26% to the total ARR[28] - Customers with more than 10 users account for 80% of the total ARR[28] Financial Performance - The company has demonstrated consistent incremental revenue growth, as shown by the increase from $161 million in FY20 to $972 million in FY24[35] - The annual revenue shows a CAGR of 57% from 2020 to 2024[35] - Adjusted free cash flow for Q2 2025 was $641 million, representing 21% of revenue[5, 47]

Financial Outlook for 2025 - Revenue is projected to be between $2.76 billion and $2.82 billion[7] - Adjusted EBITDA is expected to range from $376 million to $382 million[7] - Adjusted Net Income is forecasted to be between $81 million and $85 million[7] - Adjusted EPS is anticipated to be in the range of $1.02 to $1.07[7] Key Financial Metrics - Interest Expense is estimated to be $97 million to $100 million[7] - Gross Capital Expenditures are projected to be $205 million to $215 million[7] - Net Capital Expenditures are expected to be $135 million to $145 million[7] - The Adjusted Effective Tax Rate is projected to be between 29.5% and 30.5%[7] - Diluted Weighted Average Shares Outstanding are estimated to be approximately 80 million[7] Important Considerations - The company's outlook includes forward-looking statements subject to risks and uncertainties, as detailed in their SEC filings[2] - The presentation includes non-GAAP financial measures used by management to evaluate performance, but these should not be considered superior to GAAP measures[3, 5]

Transaction Overview - Western Union will acquire International Money Express for $1600 per share in cash[16] - The transaction is expected to close in mid-2026, pending regulatory approvals and closing conditions[18] - The acquisition is expected to yield $30 million in annual run-rate cost synergies within 24 months[16] - The transaction is expected to be immediately EPS-accretive[17] Strategic Benefits - The acquisition increases scale in high-growth LACA geographies through complementary agent networks[17] - It expands and stabilizes Western Union's U S retail footprint, enhancing resilience and improving customer access across the Americas[17] - The combined company is projected to have approximately 70000 send locations[25] - The combined company is projected to have approximately 21 million customers[25] - The combined company is projected to have approximately $2100 million in revenue[25] Financial Impact - The transaction is expected to drive an incremental $010 of Adjusted EPS in the first full year[31] - The acquisition strengthens long-term Free Cash Conversion[35]

August 11, 2025 Second Quarter 2025 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes 1 Agenda | 1 | Opening Remarks | | --- | --- | | 2 | Q2 2025 Highlights & Recent Accomplishments | | 3 | Our Pipeline | | 4 | Capitalizing on Market Leadership | | 5 | CARVYKTI® Performance Overview | | 6 | Financial Performance | | 7 | Q&A | 2 This presentation is for investor relations purposes only - Not for product promotional purposes ...

Financial Performance - Q2 2025 revenue was $20.5 million, compared to $23.1 million in Q2 2024[6] - Gross margin in Q2 2025 was 56.4%, compared to 57.2% in Q2 2024[6] - Adjusted EBITDA for Q2 2025 was $1.5 million, compared to $1.3 million in Q2 2024[6] - Q3 2025 revenue is projected to be in the range of $19 million to $21 million[16] - Q3 2025 gross margin is projected to be in the range of 56% to 58%[16] Regional Performance - APAC region experienced a 25.4% year-over-year decrease in Q2 2025, but with a 1.1% increase from F/X[7] - EMEA region was relatively flat, with a 0.3% year-over-year decrease in Q2 2025, but with a 5.0% increase from F/X[7] - US Pre-Clinical declined 11.7% year-over-year in Q2 2025[7] Strategic Focus - The company is prioritizing stabilizing the core business and restructuring the balance sheet to build sustainable sales and profitability[19] - The company is positioning the business for renewed growth and margin expansion in 2026 and beyond[19] - The company is focused on accelerating product adoption by leveraging a strong and innovative pipeline[19]